| Study |
Design&Duration |
Comb:BA ratio |
Outcomes |
Pooled summary stats |
SIngle study results |
Stat sig? |
Comment |
| Wolstenholme 1989
Tammivaara 1993 |
Crossover trial
4 weeks
Crossover trial
3 weeks |
1:1
1:1
ORAL CR
terbutaline |
Patient preference |
|
OR 0.79
95%CI 0.20, 3.06
OR 1.70
95%CI 0.40, 7.20 |
N
N |
1.3 times worse with AC/BA
1.7 times better with AC/BA |
| Philip Joet 1990 |
Parallel design
8 weeks |
1:2 |
Number of patients with exacerbations |
|
OR 1.70
95%CI 0.64, 4.51 |
N |
1.7 times worse with AC/BA |
| Tammivaara 1993 |
Crossover trial
3 weeks |
1:1 CR
ORAL terbutaline |
Number of patients with exacerbations
No. withdrawing due to treatment failure |
|
OR 0.32
95%CI 0.01, 8.24
OR 0.32
95%CI 0.01, 8.24 |
N
N |
3 times better with AC/BA
3 times better with AC/BA |
| Rebuck 1983 |
Crossover trial
4 weeks |
1:1 |
No. withdrawing due to treatment failure |
|
OR 2.10
95%CI 0.18, 25.01 |
N |
2 times worse with AC/BA |
| Haahtela 1991 |
Parallel trial
12 weeks |
1:1 Duovent / Sal |
No. withdrawing due to treatment failure |
|
OR 5.09
95%CI 0.98, 26.43 |
N |
5 times worse with AC/BA |
| Haahtela 1991 Philip‐Joet 1990 |
Parallel trial 12 weeks Parallel trial 8 weeks |
1:2 Berod/Sal 1:2 Berod/Sal |
Number of patients withdrawing due to treatment failure |
OR 1.40 95%CI 0.69, 2.84 2 studies, 256 patients; Heterogen. p=0.22, I‐squared =32.2% |
|
N |
1.4 times worse with AC/BA |
| |
|
|
|
|
|
|
|
